3 British AI Healthcare Stocks With Revenue Growth Up To 14%

AI spending is now a meaningful driver of US economic growth, and that wave of investment is rippling into healthcare technology worldwide. For UK investors, companies using artificial intelligence to tackle diagnosis, treatment and hospital efficiency offer exposure to that trend without relying on a single US software giant. This article highlights three AI powered healthcare stocks from our British-focused screener that could merit a closer look.

The stocks below are just a starting sample from this theme. The full screen surfaced 4 more healthcare AI companies with equally compelling narratives that are not covered in this article.

To identify and analyze those higher conviction opportunities alongside the ideas discussed here, head straight into the Transformative Artificial intelligence (AI) Healthcare Stocks screener

Haleon (LSE:HLN)

Overview: Haleon is a global consumer healthcare group that uses AI enabled data and its Microsoft partnership to refine oral care, vitamins and over the counter treatments, while focusing on more personalised products and sharper supply chains.

Operations: Haleon generates about £3.8b from North America, £4.7b from EMEA and Latin America, and £2.6b from Asia Pacific.

Market Cap: £30.8b

Haleon matters in this AI healthcare theme because its Microsoft collaboration brings data science and automation into everyday consumer health decisions, turning product launches, supply chains and marketing into a test case for how AI can quietly reshape over the counter care at scale.

"Although Haleon continues to talk up premium, clinically supported oral health launches that have historically outgrown the wider category, the group is still only delivering 2.6% organic revenue growth in the first half of 2026 against a 4% to 6% ambition."

For Haleon, a single unresolved question around whether efficiency gains outpace the cost of funding them could be decisive for long term profitability.

If that balance between AI driven efficiencies and funding costs is what you care about, go straight to the full narrative for Haleon to see how the story could evolve next.

IXICO (AIM:IXI)

Overview: IXICO runs an AI enabled neuroimaging platform and imaging services that help drug developers measure brain changes in neurological disease trials.

Operations: IXICO generates about £7 million of revenue from medical labs and research services built around neuroimaging analytics and clinical trial support.

Market Cap: £17 million

IXICO is closely aligned with the Transformative AI Healthcare theme through its AI powered brain imaging biomarkers for conditions such as Alzheimer’s and Parkinson’s. The company remains loss making and has underperformed wider UK life sciences. For investors, the potential appeal is evident; however, outcomes are influenced by how pressure on future profitability is addressed.

That pressure on future profitability is exactly why many investors are scrutinising IXICO right now, and the analysis report for IXICO lays out how the AI trial pipeline could reshape the story.

AstraZeneca (LSE:AZN)

Overview: AstraZeneca develops, manufactures, and sells prescription medicines across oncology, cardiovascular, respiratory, vaccine, and rare disease treatments worldwide.

Operations: AstraZeneca generates about $61.4b of revenue from pharmaceuticals, with earnings and R&D closely tied to prescription drug development.

Market Cap: £186.1b

For this AI healthcare theme, AstraZeneca matters because its Tempus and Pathos partnership aims to bring foundation model style intelligence directly into cancer diagnosis and treatment choices rather than just back office efficiency tools.

"Ongoing investments in transformative technologies (such as next-generation ADCs, bispecific antibodies, mRNA platforms, and AI/digital-enabled clinical trial efficiencies) are expected to accelerate drug development cycles, enable precision medicine launches, and support higher net margins due to more efficient R&D and premium pricing potential."

The real swing factor is how one concentrated bet on AI guided oncology research ultimately feeds through to pricing power and long term earnings quality.

That earnings quality question is exactly what sits at the centre of the full narrative for AstraZeneca, which maps how AstraZeneca’s AI oncology bets could accelerate or stall the story.

Curious About Alternative Market Paths?

Fresh themes move first, and the early momentum often goes to investors who spot under the radar ideas before the crowd while it matters. Review these screens and get in early.

• Hunt for mispriced quality by scanning a curated 6 high quality undervalued stocks. It filters for strong cash generation and balance sheets before momentum starts flying.
• Target resilient cash returns by reviewing a hand picked 1 dividend fortresses. It is built around established payouts that could matter when share prices start dropping.
• Track the next automation wave by assessing a refined list of 91 robotics and automation stocks. It is positioned around real-world industrial and logistics use cases while they are still under the radar for now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com